Vistagen Therapeutics, Inc. (VTGN) Total liabilities 2016–2026
Vistagen Therapeutics, Inc. (VTGN) total liabilities at each fiscal year-end, per SEC filings.
$13.0MFY2026 · since FY2016: $4.0M → $13.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $13.0M | -6.5% |
| FY2025 | $14.0M | +48.9% |
| FY2024 | $9.4M | +4.0% |
| FY2023 | $9.0M | -9.3% |
| FY2022 | $9.9M | -39.1% |
| FY2021 | $16.3M | +41.7% |
| FY2020 | $11.5M | — |
| FY2018 | $4.4M | +40.9% |
| FY2017 | $3.1M | -21.9% |
| FY2016 | $4.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice